|
Malignant Head and Neck Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
This review article will discuss recent multilateral efforts to discover and validate actionable strategies that involve signaling pathways in heterogenous head and neck cancer and to overcome anti-EGFR resistance in the era of precision medicine.
|
30700700 |
2019 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the cooperative role of SAHA and the EGFR tyrosine kinase inhibitor gefitinib in both HPV-positive and HPV-negative HNC cell lines.
|
30765872 |
2019 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This phase I/II trial evaluated the combination of cetuximab with IL12 for the treatment of EGFR-expressing head and neck cancer.
|
31142501 |
2019 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cetuximab, the IgG1 subclass chimeric mouse-human monoclonal antibody biologic that targets the epidermal growth factor receptor (EGFR), is used worldwide for the treatment of EGFR-positive unresectable progressive/recurrent colorectal cancer and head and neck cancer.
|
31053502 |
2019 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Patient-Derived Head and Neck Cancer Organoids Recapitulate EGFR Expression Levels of Respective Tissues and Are Responsive to EGFR-Targeted Photodynamic Therapy.
|
31694307 |
2019 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cetuximab is a common EGFR monoclonal antibody used with radiotherapy to treat head-and-neck cancer.
|
30614125 |
2019 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
To the best of our knowledge, the application and development of EGFR‑targeted peptide‑conjugated liposome system for RSV delivery has not been studied previously in the treatment of head and neck cancer.
|
30816515 |
2019 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Bosutinib Inhibits EGFR Activation in Head and Neck Cancer.
|
29933569 |
2018 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
EGFR overexpression is not common in patients with head and neck cancer. Cell lines are not representative for the clinical situation in this indication.
|
29989001 |
2018 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cetuximab is a monoclonal antibody against epidermal growth factor receptor and is used in the treatment of head and neck cancer, non-small cell lung cancer, and colorectal cancer.
|
29157147 |
2018 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The objectives of the study are to identify and characterize two head and neck cancer cell lines with regard CD44<sup>high</sup>/CD133<sup>high</sup>/CD117<sup>high</sup> profile (CSCs) and CD44<sup>low</sup>/CD133<sup>low</sup>/CD117<sup>low</sup> profile (Non-CSCs); to investigate the influence of chemotherapy treatment in CSCs and compare with Non-CSCs; to evaluate CD44 and EGFR gene expression in CSCs.
|
30210931 |
2018 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.
|
30291796 |
2018 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
These data suggest the importance of an appropriate timing administration between an EGFR inhibitor and a conventional chemotherapy in order to obtain the best clinical benefit for patients with a head and neck cancer.
|
30345256 |
2018 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Relative EGFR density and cell binding assay was conducted in three human head & neck cancer cell lines (scc-U2, scc-U8, and OSC19) and one reference cell line A431.
|
29777587 |
2018 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Role of EGFR as prognostic factor in head and neck cancer patients treated with surgery and postoperative radiotherapy: proposal of a new approach behind the EGFR overexpression.
|
28452036 |
2017 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K<sub>521</sub> Polymorphism.
|
28031227 |
2017 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inhibition of epithelial-mesenchymal transition by cetuximab via the EGFR-GEP100-Arf6-AMAP1 pathway in head and neck cancer.
|
27880014 |
2017 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer.
|
28102297 |
2017 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer.
|
28196873 |
2017 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, a minority of patients with head and neck cancer are unresponsive to EGFR targeting therapies.
|
28810546 |
2017 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies.
|
28382569 |
2017 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is commonly upregulated in cancers such as in non-small-cell lung cancer, metastatic colorectal cancer, glioblastoma, head and neck cancer, pancreatic cancer, and breast cancer.
|
28513565 |
2017 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer.
|
28352657 |
2017 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cetuximab, an EGFR-specific antibody (mAb), modestly improves clinical outcome in patients with head and neck cancer (HNC).
|
27496866 |
2017 |
|
Malignant Head and Neck Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
ELISpot was carried out to quantify EGFR-specific T cells in nimotuzumab-treated head and neck cancer (HNSCC) patients.
|
28674498 |
2017 |